Timothy Stenzel, M.D., Ph.D.

Throughout his career as an executive leader with deep scientific expertise, Tim has helped many organizations create and launch innovative products and services that form new lines of business driving high revenue growth. Tim is the former director of the US Food and Drug Administration’s (FDA) Office of In Vitro Diagnostics and has an extensive scientific background in molecular diagnostics, genetics, oncology and infectious diseases. During his five-year tenure at the FDA, he led a team of almost 300 scientists and was known for working with multiple constituencies to create solutions to secure patient access to reliable tests.

Prior to his government service, Tim held leadership roles in both industry and academia. As the chief operating officer of Invivoscribe, he helped to launch more than 22 new products and services, including an FDA-approved companion diagnostic for Novartis’ drug Rydapt (midostaurin). While serving as the chief scientific officer of Quidel Corporation, he led the creation of their molecular diagnostics franchise, which now has more than 23 cleared products with significant revenue. Tim also served on the Duke University School of Medicine faculty for 21 years and founded its Clinical Molecular Diagnostics laboratory.

Tim earned his Bachelor of Arts in Chemistry with honors from Grinnell College and his MD and PhD in Microbiology and Immunology from Duke University. He was board certified in Pathology and Clinical Molecular Genetics following his residency and fellowship at Duke.